{"id":3125,"date":"2026-09-14T08:00:00","date_gmt":"2026-09-14T12:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3125"},"modified":"2026-09-14T20:29:35","modified_gmt":"2026-09-15T00:29:35","slug":"zipalertinib-extends-pfs-in-rezilient3","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3125","title":{"rendered":"Zipalertinib Extends PFS in REZILIENT3"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Taiho Pharmaceutical and Cullinan Therapeutics<\/p>\n

Event Type<\/strong><\/p>\n

Clinical Trial Results (Phase III)<\/p>\n

Modality<\/strong><\/p>\n

Oral Small-Molecule EGFR Exon 20 Insertion-Selective Inhibitor<\/p>\n

Asset<\/strong><\/p>\n

Zipalertinib (CLN-081 \/ TAS6417)<\/p>\n

Target<\/strong><\/p>\n

EGFR Exon 20 Insertion Variants<\/p>\n

Disease Area<\/strong><\/p>\n

First-Line EGFR Exon 20 Insertion-Positive Advanced Non-Small Cell Lung Cancer<\/p>\n

Summary<\/h4>\n

Zipalertinib plus platinum chemotherapy reduced the risk of progression or death by 50% versus chemotherapy alone in first-line EGFR exon 20 insertion-positive advanced NSCLC. Median PFS improved from 8.5 to 14.5 months and response rate from 40.3% to 65.0%. Interim OS favored the combination but was only 30% mature, while grade 3 or higher adverse events increased to 87.1% from 54.4%. The efficacy signal is strong; the ultimate survival and tolerability tradeoff remains open.<\/p>\n

After a six-patient safety lead-in, REZILIENT3 randomized 279 previously untreated patients to oral zipalertinib plus platinum-pemetrexed or chemotherapy alone. Median PFS was 14.5 versus 8.5 months (HR 0.50; 95% CI 0.34\u20130.73; P=0.00015). Objective response was 65.0% versus 40.3% (P<0.0001), and median response duration was 14.2 versus 9.9 months. The PFS estimate in patients with baseline brain metastases was also favorable (HR 0.38).<\/p>\n

At 30% OS maturity, the death hazard ratio was 0.72 (95% CI 0.42\u20131.23). Grade 3 or higher adverse events occurred in 87.1% versus 54.4%, dominated by hematologic events expected with chemotherapy; grade 3 or higher rash and diarrhea in the combination arm were 10.7% and 1.4%. Taiho posted the full dataset on September 14 after a September 13 U.S. partner release; the conference presentation occurred September 14 at 8:00 a.m. Korea time.<\/p>\n

Deep Analysis<\/h4>\n

One interpretation is that exon20ins-selective EGFR inhibition can establish a competitive first-line targeted regimen. The randomized PFS, response, duration, and intracranial subgroup direction support this view. The contrary evidence is immature OS and very high severe-event burden, although much appears hematologic and chemotherapy related. A second interpretation is that the combination produces a clinically meaningful PFS gain but may offer limited differentiation once survival, dose intensity, discontinuation, and quality of life are known. That caution is supported by toxicity and an active competing EGFR\/MET-antibody regimen; it is weakened by the magnitude of the PFS effect.<\/p>\n

Company and Product Background<\/h4>\n

Taiho develops zipalertinib, also known as CLN-081 or TAS6417, with Cullinan in the United States. The oral irreversible inhibitor was designed to suppress EGFR exon 20 insertion variants while limiting wild-type EGFR inhibition. These mutations alter the kinase domain, drive a distinct NSCLC subgroup, and respond poorly to conventional EGFR inhibitors.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • The result validates zipalertinib beyond early single-arm activity and supports regulatory discussions.<\/li>\n
  • Upgrades if:<\/strong> statistically persuasive OS, durable intracranial control, manageable dose modifications, and consistent benefit across exon20ins variants emerge.<\/li>\n
  • Downgrades if:<\/strong> survival converges, toxicity compromises chemotherapy exposure, or efficacy is weaker after CNS progression.<\/li>\n
  • Falsified if:<\/strong> later analyses show no net survival or patient-reported benefit relative to available targeted approaches.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    REZILIENT3 crosses the efficacy threshold expected of a first-line targeted combination. The remaining question is not whether zipalertinib adds antitumor activity, but whether that activity produces durable survival and quality-of-life value after accounting for a substantially higher severe-event rate.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal strength:<\/strong> 5\/5 \u2014 randomized global Phase III validation in a molecularly defined first-line market. Importance:<\/strong> High \u2014 large PFS and response gains support a new first-line targeted option. Confidence:<\/strong> High on facts, moderate on interpretation \u2014 company and conference disclosures are concordant, but net comparative value awaits mature survival data.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Zipalertinib plus platinum chemotherapy reduced the risk of progression or death by 50% versus chemotherapy alone in first-line EGFR exon 20 insertion-positive advanced NSCLC. Median PFS improved from 8.5 to 14.5 months and response…<\/p>\n","protected":false},"author":1,"featured_media":3130,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[754,18,755,756],"class_list":["post-3125","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-cullinan-therapeutics","tag-non-small-cell-lung-cancer","tag-taiho-pharmaceutical","tag-zipalertinib"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3125","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3125"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3125\/revisions"}],"predecessor-version":[{"id":3146,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3125\/revisions\/3146"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3130"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3125"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3125"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}